Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Target Recruit Count
- 102
- Registration Number
- NCT06254690
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast Neoplasm Female
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Wang Ouchen
- Target Recruit Count
- 154
- Registration Number
- NCT06234137
- Locations
- 🇨🇳
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Phase 4
Recruiting
- Conditions
- Advanced Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06217185
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
- Target Recruit Count
- 306
- Registration Number
- NCT06208410
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Phase 2
Not yet recruiting
- Conditions
- Disitamab VedotinERBB2 Mutation-Related TumorsNon Small Cell Lung CancerERBB2 Gene Duplication
- Interventions
- Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2023-12-29
- Target Recruit Count
- 108
- Registration Number
- NCT06185400
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Youzhi Zhu
- Target Recruit Count
- 30
- Registration Number
- NCT06035679
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujan Medical University, Fuzhou, Fujian, China
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Recruiting
- Conditions
- Early-stage Breast CancerHER2-positive Breast Cancer
- Interventions
- Drug: treatment of physician's choice
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06035016
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 488
- Registration Number
- NCT05910398
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05880927
- Locations
- 🇨🇳
Taizhou Hospital, Taizhou, Zhejiang, China
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 876
- Registration Number
- NCT05841381
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath